Post Inspection Summary Multiple Sites Conducted 1st Quarter 2026

🎯 Purpose of This Report

This report reflects aggregated, anonymized insights gathered through post-inspection interviews with Mammologix clients following their MQSA inspections during the first quarter of 2026.

Our goal is simple:

Turn real inspection experiences into actionable intelligence—so every client is better prepared, more confident, and fully aligned with current expectations.

We extend our sincere appreciation to the facilities who participated. Your collaboration strengthens the entire community.

📌 PART 1 — INSPECTION THEMES & FIELD OBSERVATIONS

🔍 What Inspectors Focused On

Across all sites, inspectors demonstrated a highly consistent and increasingly detailed focus in the following areas:

👥 Personnel Credentials & Documentation (Primary Focus Area)

• Radiologist training documentation—especially clear distinction between 2D vs. 3D training hours
• CME documentation and precise attestation wording
• Radiologist read volumes—with new emphasis on site-specific volume validation, not aggregate totals
• Evidence of direct supervision where applicable

🧪 QC & EQUIP Processes

• Completeness of EQUIP documentation (including all interpreting physicians)
• Strict adherence to QC schedules (monthly, semiannual, etc.)
• Increased enforcement of manufacturer-specific QC requirements
  • Example: Curved paddles must be tested and documented by the physicist

🖥️ Workstation & Monitor Documentation

• Detailed scrutiny of:
  • Monitor QC logs
  • Workstation identification

• Remote reading locations must include full physical address

  (generic labels like “home workstation” are no longer acceptable)

📚 Manuals & Equipment Documentation

• Operator manuals must be:
  • Immediately accessible
  • Aligned with current software versions
• Technologists are increasingly being asked to demonstrate access in real time

📄 Documentation Accuracy & Consistency

• Inspectors are:
  • Cross-referencing reports, logs, and activity
  • Reviewing documentation line-by-line
• Common issue:
  • Incorrect year entries (especially in January transitions)

⚠️ Unexpected / Emerging Inspection Requests

Even in “routine” inspections, several new or intensified expectations emerged:

• Site-specific radiologist volume breakdowns
• Strict attestation language requirements, including:
  • CME specificity
  • Modality distinction (2D vs 3D)
  • Supervision statements
• Documentation for:
  • Outsourced workflows
  • Breast biopsy processes
  • Follow-up tracking systems
• New equipment documentation:
  • Installation records
  • State registration forms
• Physicist oversight:
  • Documentation of trainee work under supervision
• External vendor documentation:
  • Updated QC reports
  • Credential verification

🚨 Findings & Risk Areas

📉 Most Common Issues (Clerical → Potential Citations)

• Missing or incomplete dates (including full year)
• Inconsistent report dating
• Use of white-out in QC logs (frequently flagged)
• Facility naming inconsistencies across documents

👉 These issues approached Level 2 citations in multiple cases.

🔴 Credentialing Risks (High-Risk Category)

• Missing radiologist training documentation (2D/3D)
• Non-compliant attestation wording
• Missing physicist credentials
• Incomplete QC reporting

⚙️ QC & Compliance Violations

• Missed QC testing (e.g., compression testing) → Level 2 citations issued
• Insufficient QC log detail (traceability gaps)
• Failure to follow manufacturer QC specifications exactly

📂 Documentation & System Gaps

• Delays in receiving:
  • Radiology group documentation
  • Physicist reports
  • Vendor deliverables
• Outdated or incomplete external QC documentation

🧠 Operational Strengths vs Weaknesses

✅ What High-Performing Sites Did Well

• Organized, structured documentation systems (digital or binder)
• Clearly labeled and easy-to-navigate records
• Immediate retrieval of requested documents

⚠️ Common Weaknesses

• Inconsistent formatting across logs or rooms
• Reactive (not proactive) documentation practices
• Poor coordination with external partners

📘 Lessons Learned (Across All Sites)

• Credentialing must be exact—not assumed
• Wording matters (especially training and CME documentation)
• QC compliance must be proactive
• Missed QC tests = automatic citation risk
• Small clerical errors can escalate quickly
• External partners represent a significant vulnerability
• Organization directly reduces inspection intensity

📊 PART 2 — KEY TRENDS

👥 Personnel & Credentialing (Top Risk Area)

• Most heavily scrutinized category
• Key issues:
  • Training documentation gaps
  • Attestation inaccuracies
  • Volume validation inconsistencies

🧪 QC Documentation & Compliance

• Inspectors:
  • Review logs line-by-line
  • Compare directly to manufacturer requirements
• Even minor issues (e.g., white-out, missing year) are flagged

📚 Manuals & Equipment Documentation

• Manuals must:
  • Match current software versions
  • Be immediately accessible
• Inspectors are validating this in real-time

🧭 Executive-Level Takeaways

1. 🚨 Top Drivers of Citations

• Missed QC tests
• Credentialing gaps
• Documentation inconsistencies

New Critical Trend:

• Enforcement of breast density notification compliance (effective Sept 10, 2024)
  • Facilities are now being cited for single-instance violations

2. ⚠️ Top “Near Miss” Risks

• Naming inconsistencies (letters vs FDA certificate)
• Missing or incorrect training language
• External vendor documentation gaps

3. 📈 Biggest Shift in 2026

• Increased scrutiny on:
  • Personnel credentialing
  • Monitor QC and workstation documentation
  • Precision of documentation—not just presence

🔑 Final Perspective

The direction is clear:

MQSA inspections are no longer just about having documentation—they are about precision, traceability, and proof of compliance at every level.

Facilities that succeed are those that:

• Build systems—not just files
• Validate continuously—not just before inspection
• Align internal teams and external partners

🤝 Mammologix Commitment

We are actively integrating these insights into our services, tools, and client support systems to ensure you remain:

• Inspection-ready
• Operationally efficient
• Fully aligned with evolving MQSA expectations

If you have questions about how these findings apply to your facility—or want help closing gaps—we are here to support you.

Disclaimer

The information contained in the MQSA Inspection Insights Report is provided for informational purposes only and is based on anonymized feedback voluntarily shared by Mammologix clients following their MQSA inspections. This report is not intended to replace official rules, regulations, or guidance issued by the U.S. Food and Drug Administration (FDA), state regulatory agencies, or other governing bodies.

While the content reflects real-world observations and common inspection experiences, it should not be interpreted as a comprehensive or authoritative source of regulatory requirements. Inspection practices may vary, and interpretations of compliance standards are subject to change.

Users are strongly encouraged to consult the official MQSA regulations and seek guidance directly from the FDA or appropriate state authorities regarding any specific compliance questions or interpretations.

Mammologix makes no representations or warranties regarding the completeness, accuracy, or applicability of this information to any individual facility's circumstances. Use of this report is at your own discretion and risk.